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Peroxisome proliferator-activated receptor gamma (PPARγ) activation decreased serum testosterone (T) in women with
hyperthecosis and/or polycystic ovary syndrome and reduced the conversion of androgens to estradiol (E2) in female rats. This
implies modulation of female sex steroid hormones by PPARγ. It is not clear if PPARγ modulates sex steroid hormones in diabetic
males. Because PPARγ activation by thiazolidinedione increased insulin sensitivity in type 2 diabetes, understanding the long
term impact of PPARγ activation on steroid sex hormones in males is critical. Our objective was to determine the eﬀect of PPARγ
activationonserumandintratesticularT,luteinizinghormone(LH),folliclestimulatinghormone(FSH)andE2concentrationsin
maleZuckerdiabeticfatty(ZDF)ratstreatedwiththePPARγ agonistrosiglitazone(athiazolidinedione).Treatmentforeightweeks
increased PPARγ mRNA and protein in the testis and elevated serum adiponectin, an adipokine marker for PPARγ activation.
PPARγ activation did not alter serum or intratesticular T concentrations. In contrast, serum T level but not intratesticular T was
reduced by diabetes. Neither diabetes nor PPARγ activation altered serum E2 or gonadotropins FSH and LH concentrations. The
results suggest that activation of PPARγ by rosiglitazone has no negative impact on sex hormones in male ZDF rats.
Copyright © 2009 Mahmoud Mansour et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Peroxisome proliferator-activated receptors (PPARs) are a
group of nuclear transcription factors which belong to the
steroid receptor superfamily but are not activated by steroid
hormones. Three PPAR isotypes have been identiﬁed and
include PPARα (NR1C1), PPARβ (NR1C2, δ, NUC-1, fatty
acid-activated receptor (FAAR)), and PPARγ (NR1C3). A
large number of both endogenous (natural) and exogenous
(synthetic) ligands activate either a single PPAR isoform
or all isoforms, albeit with diﬀerent binding aﬃnities and
speciﬁcities [1]. Among the important PPARγ synthetic
activators are the thiazolidinediones (TZDs) drugs often
used in the treatment of type 2 diabetes. These include
Avandia (rosiglitazone), Actos (pioglitazone), a combina-
tion drug, Avandamet (rosiglitazone and metformin), and
Rezulin (troglitazone). Troglitazone was withdrawn from
the market because of idiosyncratic liver toxicity. Activation
of PPARγ by TZDs increases insulin sensitivity and thus
improves body glycemic control [2, 3].
PPARs are involved in a broad range of functions that
include lipid homeostasis [2], tissue remodeling, angiogen-
esis, prostaglandin production [3], and steroidogenesis [4].
Additionally, PPARs also regulate inﬂammatory pathway by
transrepression of transcription activity of proinﬂammatory
transcription factors such as nuclear factor κB( N F - κB)
[5]. Likewise, several data implicate PPARs in regulation of
proﬁbrotic [6–8] and oxidative stress responses in several cell
types [9–11].
Support for the hypothesis that activation of PPARs,
speciﬁcally PPARγ, has an impact on sex steroid hormones
action and/or production comes from several TZDs stud-
ies including two studies in male subjects [4, 12–22]. A
study in healthy nondiabetic men showed that rosiglitazone
treatment (8mg/d for seven days) reduced the production
rate of testosterone (T) and dihydrotestosterone (DHT)2 PPAR Research
[14]. Similarly, rosiglitazone treatment of obese nondiabetic
Zucker rats (0.01%wt/wt food admixture equivalent to
4mg/kg/d for 36 days) reduced DHT but did not alter serum
T[ 22].
Multiple studies using ovarian and other cell culture
models support a steroidogenic role for PPARγ. First,
activation of PPARγ with troglitazone, a TZD insulin sen-
sitizer and putative PPARγ agonist, inhibited aromatase
cytochrome P450 activity, the enzyme critical in the con-
version of androgens to estradiol (E2), in human adipose
tissue [15] and in ovarian granulosa cells [20]. Similarly,
activation of PPARγ by troglitazone in vitro cultures of
human and porcine granulosa cells inhibited progesterone
production [4]. Troglitazone was also reported to compet-
itively inhibit 3β-hydroxysteriod dehydrogenase (3β-HSD),
the enzyme that catalyzes the conversion of pregnenolone
to progesterone in the ovary [16]. Likewise, troglitazone
was shown to inhibit androgen biosynthesis stimulated by
combined LH and insulin in primary porcine thecal cell
culture in a dose-dependent fashion [17].
In human adrenal NCI-H295R cells, an established in
vitro model of steroidogenesis of the human adrenal cortex,
both rosiglitazone and pioglitazone inhibited the activities of
P450c17 and 3β- H S Dt y p eI Ib o t ho fw h i c ha r ek e ym i c r o -
somal enzymes in the biosynthesis of all steroid hormones
[18]. In diabetic women with polycystic ovarian syndromes
(PCOs), a condition characterized by anovulatory androgen
secretion, relatively high E2, and excessive LH production
[23–25], treatment with the PPARγ agonists rosiglitazone
or pioglitazone improved insulin resistance and decreased
hyperandrogenisminmultiplestudies(reviewedin[26–28]).
Toxicological studies showed that phthalate esters, used
as plasticizers and stabilizers in several consumer products,
activate PPARγ [29], decrease key testicular steroidogenic
enzymes [30] and reduce serum T production [31–34].
Although it is axiomatic that steroidogenic inhibition
is a general characteristic of TZD compounds, involvement
of PPARγ and rosiglitazone in steroidogenic modulation
under diabetic conditions remains unclear for several
reasons. First, a study showed that the in vitro IC50
for rosiglitazone steroidogenic inhibition is far beyond
its recommended therapeutic dose [13]. Second, a num-
ber of studies showed that TZDs, including rosiglita-
zone, directly inhibit 3β-HSDII and P450c17 steroidogenic
enzymes independent of PPARγ [13, 18]. Third, in the
aforementioned male studies PPARγ activation was not
determined in parallel with sex hormone measurements.
More importantly none of the research subjects used
was diabetic where the steroidogenic eﬀect of diabetes
is an important component for evaluation of TZDs-
PPARγ activators. Finally, the treatment period used in
the aforementioned male studies was short and varies
between 7 and 36 days. Because of the above limita-
tions, the objective of this study was to determine the
link between relatively short term (8 weeks) activation
of PPARγ and the proﬁle of T and E2 in male Zucker
diabetic fatty rats (ZDFs) treated with a therapeutic dose of
rosiglitazone.
2.MaterialsandMethods
2.1. Animals and Treatments. Male ZDF (fa/fa) rats and their
age-matched lean controls (ZDF lean, fa/+ or +/+) were
obtained from Charles River Laboratories (Indianapolis,
Ind, USA) at 6 weeks of age. The (fa/fa) ZDF rats lack
a functional leptin receptor and become hyperphagic and
diabetic when fed a high fat diet. Rats were maintained
under standard housing conditions (constant temperature of
22
◦C, ad libitum food and water, and 12:12 hours light/dark
cycles) at an AAALAC-accredited lab animal facility at the
College of Veterinary Medicine, Auburn University. Rats
were housed in pairs and assigned to three groups with
8 rats per group. Lean nondiabetic group (group 1); ZDF
rats randomly assigned to ZDF untreated group (group
2) and ZDF group treated with rosiglitazone (group 3).
Lean rats were fed regular rat chow whereas ZDF rats in
group 2 and 3 were fed Purina 5008 modiﬁed rat chow
(Purina Mills, Richmond, Ind, USA). Rosiglitazone maleate
(generously provided by GlaxoSmithKline, USA) was dis-
solved in 0.5% carboxymethylcelluose and administered
daily via oral gavage at 3mg/kg/d/rat starting at week 7
of age for 8 weeks. Rats in groups 1 and 2 received 0.5%
carboxymethylcelluose vehicle. All rats were weighed and
blood glucose was monitored from the tail vein weekly
using an ACCU-CHEK glucose meter (Roche Diagnostics
Co. Indianapolis, Ind, USA). Diabetes was conﬁrmed by two
consecutive measurements of blood glucose of >200mg/dl.
All animal procedures were approved by the Institutional
Animal Care and Use Committee at Auburn University.
2.2. Necropsy and Tissue Collection. Rats were sacriﬁced
by deep anesthesia with pentobarbital (50mg/kg intraperi-
toneal, IP) followed with decapitation. Testes were excised,
and sampled for histopathology, RNA extraction, and intrat-
esticular T assay. Visceral epididymal fat and prostate were
collected for use as positive sources for PPARγ expression
in real-time PCR analysis. Tissues intended for RNA and
hormoneanalysiswereimmediatelyfrozeninliquidnitrogen
and transferred to −80
◦C until processing. Trunk blood was
collected for serum isolation and stored at −30
◦Cp r i o rt o
hormone analysis.
2.3. Total RNA Isolation. Total RNA was isolated using
TRIzol reagent (Invitrogen-Life Technologies Inc., Carlsbad,
Calif, USA), according to the manufacturer’s instructions
and as described previously in our laboratory [35]. Brieﬂy,
RNA concentrations were determined at 260nm wavelength
and the ratio of 260/280 was obtained using UV spectropho-
tometry (DU640, Beckman Coulter Fullerton, Calif, USA).
RNA samples were treated with DNase (Ambion Inc.) to
remove possible genomic DNA contamination and samples
with 260/280 ratio of ≥1.8 were used.
2.4. Real-Time PCR and Agarose Gel Electrophoresis. Real-
time PCR was used to determine expression of testicu-
lar PPARγ mRNA and to quantify changes in mRNA
level. Quantitative real-time PCR analysis was performedPPAR Research 3
in 25μL reaction mixture containing RT2 Real-Time
SYBR/Fluorescein Green PCR master mix with ﬁnal con-
centrations of 10mM Tris-Cl, 50mM KCL, 2.0mM MgCl2,
0.2mM dNTPs, and 2.5 units of HotStart Taq DNA poly-
merase (Super Array Bioscience Corporation, Frederic, Md,
USA). The reaction was completed with addition of 1μL
ﬁrst strand cDNA transcribed from 2μg total RNA, and
0.2mM RT2 validated PCR primers for PPARγ or GAPDH
house keeping gene (Super Array Bioscience). Samples were
run in 96-well PCR plates (Bio-Rad, Hercules, Calif, USA)
in duplicates, and the results were normalized to GAPDH
expression. The ampliﬁcation protocol was set at 95
◦Cf o r1 5
minutes, and 40 cycles each at (95
◦C for 30 seconds, 55
◦Cf o r
30 seconds, and 72
◦C for 30 seconds) followed by a melting
curve determination between 55
◦Ca n d9 5
◦Ct oe n s u r e
detection of a single PCR product. Real-time PCR products
at the end of each assay were combined for each treatment
group and stored at −30
◦C for viewing on agarose gel
electrophoresis. Veriﬁcation of PCR product was conﬁrmed
bydeterminationofexpectedbandsizeandsequenceanalysis
as we described previously [35]. The resulting sequences
were matched with previously published rat sequences in
Genbank (accession number NM 013124 for PPARγ) using
Chromas 2.31 software (Technelysium Pty ltd, Tewantin Qld
4565, Australia). RNA templates from white adipose tissue
and prostate were used to generate standard curves for
PPARγ and GAPDH using 10-fold dilutions. Curves were
made by plotting threshold cycle (Ct value) for each dilution
versus the log of the dilution factor used. Relative diﬀerences
in expression (fold increase or decrease) were calculated as
described previously [36]. Pearson correlation coeﬃcients (r
values) for standard curves were between 0.98 and 0.99, and
ampliﬁcation eﬃciency was considered 100%.
2.5. Immunohistochemistry (IHC). Immunolocalization of
PPARγ b yI H Cw a sp e r f o r m e da sd e s c r i b e dp r e v i o u s l yb y
our laboratory [35]. Brieﬂy, cross sections from testes were
ﬁxed in 4% paraformaldehyde for 48 hours, embedded in
paraﬃn,andcutat5μmthickness.Sectionswerealsoﬁxedin
Bouin’s ﬁxative (BioSciences) for staining with hematoxylin
and eosin. Mounted sections were deparaﬃnized in Hemo-
D (Scientiﬁc Safety Products) and hydrated in distilled
water. Antigen retrieval was performed by heating in citrate
buﬀer. Sections were incubated in 5% normal goat serum
containing 2.5% BSA to reduce nonspeciﬁc staining. PPARγ
was detected with mouse anti-PPARγ monoclonal antibody
(Santa Cruz: sc7273; diluted 1:80 in blocker) and the
antibody-antigen complexes were visualized with Alexa 488-
conjugated goat antimouse IgG (Molecular Probes). Sections
were examined with a Nikon TE2000E microscope and
digital images were made with an attached Retiga EX CCD
digital camera (Q Imaging, Burnaby, BC, Canada).
2.6. Hormonal Assays. Total serum T (intraassay coeﬃcient
of variation (CV) was 4.3%), E2 (intraassay CV was 2.3%),
and intratesticular (intraassay CV was 6%) level were deter-
mined by radioimmunoassay (RIA) using kits from Siemens
Medical Solutions Diagnostics (Los Angles, Calif, USA)
according to manufacturer’s instructions. For intratesticular
T, 100mg of testicular tissue was homogenized in 500μL
Tris-PBS buﬀer (0.01M Tris-HCl; pH 7.4) in plastic tubes.
An additional 500μL was added and the homogenate was
mixed with eight volumes of diethyl ether. The mixture was
then vigorously vortexed and the aqueous phase quickly
frozen in a dry ice bath (70% ethanol; dry ice). Extracts were
subsequently air dried (warm bath at approximately 50
◦C
underthehood)andsamplesweresubsequentlyresuspended
in 500μL PBS-buﬀer. 50μL of 1:10 diluted sample were used
in the COAT-A-COUNT radioimmunoassay and counted in
a Cobra D5005-gamma counter (Packard Instrument Co.,
Downers Grove, Il, USA). All samples were quantiﬁed in
duplicates in a single assay. FSH and LH were determined
by radioimmunoassay at the Endocrine Laboratory, Fort
Collins, Colorado State University.
2.7. Serum Adiponectin. Total serum adiponectin concentra-
tion was assayed using a sandwich ELISA method (Milli-
pore Corporation, Billerica, Mass, USA) per manufacturer’s
instructions. The intraassay CV was 1.1% to 1.3%.
2.8. Statistical Analysis. Analysis of real-time PCR data
was performed using a modiﬁcation of the delta delta Ct
method (ΔΔCt). ΔCt calculated from real-time PCR data
were subjected to analyses of variance using Sigma Stat
statisticalsoftware(JandelScientiﬁc,Chicago,IL).Hormonal
data were subjected to analysis of variance. Treatment
groups with means signiﬁcantly diﬀerent (P<. 05) from
controlswereidentiﬁedusingDunnett’stest.Whendatawere
not distributed normally, or heterogeneity of variance was




5008 high fat diet in groups 2 and 3 became diabetic by
w e e k7o fa g e .B yw e e k1 5o fa g et h em e a nb l o o dg l u c o s e
concentration, determined shortly before necropsy, was
>600mg/dl (above glucose meter range) in ZDF-untreated
controls (group 2) versus 123±1.7mg/dl in lean nondiabetic
controls (group 1) and 163.6 ± 17.7 in ZDF rats treated
with rosiglitazone (group 3). Rats in all three experimental
groups gained weight over time irrespective of treatment.
The ZDF-untreated rats mean body weight at week 15 was
not signiﬁcantly diﬀerent from lean nondiabetic (382.75 ±
10.94 versus 365 ± 8.2gm, resp.; P>. 05). In contrast,
the mean body weight of ZDF treated rats (group 3) was
more than 40% above that of ZDF untreated rats at week 15
(638.6 ±14.67 versus 382.75 ±10.9gm,P<. 001).
3.2. Serum Adiponectin. Serum adiponectin was determined
to conﬁrm PPARγ activation [37]. As expected, treatment
with rosiglitazone increased serum adiponectin signiﬁcantly
in ZDF-treated compared with ZDF-untreated rats (46.33 ±
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Figure 1: (a) Real-time PCR analysis of testicular PPARγ mRNA levels in lean nondiabetic controls (Lean C), Zucker diabetic fatty (ZDF)
untreated (Diabetic U), and ZDF rats treated with rosiglitazone (Diabetic T). Data are expressed as mean ± SE. n = 8p e rg r o u p ,∗P<. 05.
(b) Agarose gel (2%) showing real-time PCR products generated in (a). Lane 1, DNA markers, lanes 2-3, RNA templates (instead of cDNA)
from fat (-VF) and prostate (-VPr) as negative controls. Lanes 4-5, fat from untreated rats (FU) and prostate (Pr) as positive controls. Lanes
6–9,testicularPCRproductsfromRNAnegativecontrols(-VT),diabetictreated(DT),Diabeticuntreated(DU),andleanuntreated(LU)rats.
Lane 10, fat from ZDF-treated rats (FT). (c) Representative IHC of PPARγ protein in the testis of DT (panel 2a with insert box magniﬁed in
2b), DU (panel 3), and LU rats (panel 4). Panel 1, -VT = negative control testis section (minus primary antibody. Arrows indicate PPARγ
localization in spermatogonia and in Leydig cells.
untreated rats (46.33 ± 2.83 versus 17.13 ± 0.95μg/mL, P<
.001). In contrast, adiponectin was signiﬁcantly reduced by
diabetes in ZDF-untreated compared with lean nondiabetic
rats (17.13 ±0.95 versus 12.71 ±0.69μg/mL, P<. 05).
3.3. Real-Time PCR, Agarose Gel Electrophoresis and IHC.
Real-time PCR data showed that PPARγ mRNA was
expressed in the testis and was upregulated by more than
two folds with rosiglitazone treatment (Figures 1(a) and
1(b)). As shown in the IHC data (Figure 1(c))P P A R γ
protein was speciﬁcally localized in Leydig cells located in
the interstitial space between the seminiferous tubules and
in spermatocytes within the inside of seminiferous tubules
basement membranes.
3.4. Testicular Morphology and Histopathology. Detachment
and disorganization of germ cells was evident in ZDF-
untreated rats but there was no signiﬁcant changes in
the overall morphology of seminiferous tubules (Figure 2).
Likewise, treatment did not alter seminiferous tubules mor-
phology but desirably reversed germ cells sloughing (ZDF-
treated in panel 2 versus ZDF-untreated in panel 3).
3.5. Serum and Intratesticular T. Total serum and intrates-
ticular T were not signiﬁcantly altered by PPARγ activation
in the testis (ZDF-treated versus ZDF-untreated, P>. 05)
(Figures3 and 4). As expected total serumT wassigniﬁcantly
lowered by diabetes (ZDF-untreated or treated versus lean
nondiabetic, P<. 05) (Figure 3). Surprisingly, the signiﬁcant
reduction in total serum T in diabetic rats was not associated
with a corresponding signiﬁcant reduction in intratesticular
Tpr oduction(Figure 4).Atrendtowardlowerintratesticular
T in ZDF versus lean rats was apparent irrespective of
rosiglitazone treatment.
3.6. Serum E2. Neither diabetes nor PPARγ activation with











Figure 2: Representative photomicrographs of hematoxylin-eosin-stained sections of testis of nondiabetic Zucker lean control (Lean C,
panel 1), Zucker diabetic fatty (ZDF) untreated (Diabetic U, panel 2), and ZDF rats treated with rosiglitazone (Diabetic T, panel 3). Arrows
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Figure 3: Serum T level in Zucker lean nondiabetic controls (Lean
C), Zucker diabetic fatty- (ZDF-) untreated (Diabetic U), and ZDF
rats treated with rosiglitazone (Diabetic T). Data are expressed as
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Figure 4:Intratesticular Tlevel inZucker lean nondiabetic controls
(Lean C),Zuckerdiabeticfatty-(ZDF-)untreated(DiabeticU),and
ZDF rats treated with rosiglitazone (Diabetic T). n = 8p e rg r o u p .
Data are expressed as means ± SE.
3.7. Serum FSH and LH. Serum FSH and LH were not
signiﬁcantly altered by activation of PPARγ with rosigli-
tazone and/or by diabetes (P>. 05). The ZDF-untreated
rats, however, showed a trend for lower FSH and LH
(ZDF-untreatedversusleannondiabetic)andtreatmentwith
rosiglitazone reversed this tendency (ZDF-treated versus
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Figure 5: Serum E2 level in Zucker lean nondiabetic controls (Lean
C), Zucker diabetic fatty- (ZDF-) untreated (Diabetic U), and ZDF
rats treated with rosiglitazone (Diabetic T). n = 6p e rg r o u p .D a t a
are expressed as means ± SE.
4. Discussion
Rosiglitazone and other TZDs were shown to decrease
hyperandrogenemia in women with PCOs and repress major
steriodogenic enzymes (reviewed in [26]). Although the in
vitro steroidogenic repression potency of rosiglitazone was
ranked intermediate between troglitazone and pioglitazone
[13], its in vivo impact on sex steroids in diabetic subjects
was unknown. Speciﬁcally, information on how changes in
serum steroids in male diabetic subjects relate to changes
in PPARγ activity was lacking. This study documents the
link between testicular PPARγ activation with the anti-
diabetic drug rosiglitazone and male sex hormone proﬁle
underdiabeticconditions.DailyoralgavageofZDFratswith
rosiglitazone activated PPARγ in the testis and normalized
testicular germ cell derangement seen in diabetic testis.
The stimulation of systemic and testicular PPARγ activity
by rosiglitazone, however, did not signiﬁcantly alter the
concentrations of gonadotropins LH and FSH, sex steroid T
(both total serum and intratesticular) or serum E2.
Systemic activation of PPARγ in this study was evident
by the reversal of hyperglycemia, increased serum adipocy-
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Figure 6: Serum FSH (a) and LH (b) in Zucker lean nondiabetic controls (Lean C), Zucker diabetic fatty- (ZDF-) untreated (Diabetic U),
and ZDF rats treated with rosiglitazone (Diabetic T). n = 7-8 per group. Data are expressed as means ± SE.
rats. These eﬀects are considered biological signatures for
rosiglitazone-induced PPARγ activation in typically body
fat depots [38, 39]. Speciﬁc activation of testicular PPARγ
shown here is consistent with other unrelated studies that
showed the presence of this receptor in rat testis [40]a n d
its modulation by synthetic chemicals such as phthalate
esters [34, 41, 42]. Because PPARγ can also be activated by
endogenous ligands such as polyunsaturated fatty acids from
diet sources and by metabolites of arachidonic acid [43],
contribution of these ligands to the observed up regulation
of testicular PPARγ mRNA and protein in ZDF-treated rats
could not be ruled out.
Compared to nondiabetic lean rats, ZDF-untreated rats
showed consistent structural disorganization of germinal
epithelium evident by abnormal accumulation of germ cells
in the lumen of seminiferous tubules. This eﬀect likely
resulted from diabetes-induced oxidative stress previously
recognized in diabetic rat testis [44]. Interestingly, the
positivestainingofgermcellsforPPARγ proteininIHCdata
suggests that rosiglitazone crosses the blood-testis barrier
to enter the adluminal compartment of the seminiferous
tubules resulting in activation of PPARγ and reversal of
germ cell sloughing. This novel eﬀect is possibly mediated
by the reported functional property of PPARγ to ameliorate
oxidative stress [11].
As previously known [45], diabetes in this study signif-
icantly lowered serum T. Rosiglitazone treatment, however,
neither restored nor reduced serum T in ZDF-treated rats.
Paradoxically, the diabetes-induced reduction in serum T
in ZDF-treated and untreated rats were not associated with
a corresponding signiﬁcant drop in intratesticular T pro-
duction, or androgen receptor expression (data not shown).
Although unexpected, this ﬁnding was consistent with the
nonsigniﬁcantchangesobservedinserumLHconcentration.
The unaltered intratesticular T production contrasted with
signiﬁcantly lowered serum T concentration may reﬂect
a reduction in sex hormone binding globulin (SHBG)
essential for T transportation in blood [46]. Reagents for
determination of rat SHBG are not currently available and
attemptstoquantifyratSHBGusingahumanELISAkitwere
not successful because of reagents incompatibility.
Rosiglitazone treatment reversed obesity-induced reduc-
tion of T intermediate steroid hormone precursor 17-
hydroxyprogesterone in the genetically related obese but
nondiabetic Zucker rats [22]. In the same study, however,
rosiglitazone treatment did not alter total serum T. Com-
pared with the above ﬁndings the data in our study allow
for diﬀerentiation of diabetes steroidogenic eﬀects (ZDF-
untreatedversusleannondiabeticrats)fromthoseofPPARγ
activation (ZDF-treated versus ZDF-untreated rats) but does
not permit a way for separation of obesity eﬀects from
those of diabetes. The lack of signiﬁcant change in total
serum T in the above study was nevertheless consistent with
our ﬁndings. In both the aforementioned and our study a
tendency toward lowered serum T production was observed
in ZDF and Zucker obese versus lean littermates irrespective
of treatment. A normal transient T reduction was reported
in 2-4 months old Zucker obese rats [47]. The age of rats at
the point of serum collection in this study was 3.75 months
and thus the lowered T observed in the ZDF versus lean rats
could be a reﬂection of the above observation in these two
genetically related rat models.
Studies that support a steroidogenic regulatory role for
PPARγ in women treated with TZDs and in vitro ovarian
cell culture models have produced contrasting results as
outlined in several reviews [1, 21, 26, 27]. While some
in vitro studies showed that rosiglitazone and other TZDs
such as troglitazone could inhibit steroidogenic enzymes
independent of PPARγ activation [4, 13, 16–18, 20], an
inhibitory eﬀect of rosiglitazone was not reﬂected in total
T and E2 concentrations in ZDF-treated rats in our study.
In summary, our data show that PPARγ activation with
rosiglitazone for eight weeks had no negative impact on
total sex hormone concentrations in diabetic male rats. ThisPPAR Research 7
ﬁndingisﬁrmlyinlinewithstudiesthatshowedstrongTZD-
PPARγ activation [48, 49] but weaker in vitro steroidogenic
inhibitory eﬀects of rosiglitazone [13].
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